Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2005 Oct 19;27(4):622–625. doi: 10.1016/j.peptides.2005.09.006

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2005 Elsevier Inc. All rights reserved.

Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

PMC Copyright notice

Fig. 1 — The relation of OD₄₉₀ vs. log C showing the octapeptide's toxicity on Vero cells and the inhibitory effect of the octapeptide against SARS coronavirus in Vero cells. Here (▴) represents the normal Vero cells without infection and treated with the octapeptide (cell control OD₄₉₀ = 2.014), whereas (●) represents the infected cells treated with the octapeptide (cell control OD₄₉₀ = 2.1067; virus control OD₄₉₀ = 1.0192). Note that the two curves approach with each other when the concentration of the octapeptide gets larger, indicating that the octapeptide AVLQSGFR is an effective inhibitor against SARS-CoV.